Hefei Lifeon Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Hefei Lifeon Pharmaceutical Co Ltd working capital to net assets ratio. Hefei Lifeon Pharmaceutical Co Ltd (003020) has a Working Capital to Net Assets ratio of 36.9% as of June 2026. Working capital of CN¥730.06 Million (current assets of CN¥1.24 Billion minus current liabilities of CN¥506.50 Million) is measured against net assets of CN¥1.98 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 003020 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Hefei Lifeon Pharmaceutical Co Ltd (2012–2025)
Working capital to net assets ratio of Hefei Lifeon Pharmaceutical Co Ltd from 2012 to 2025. This chart shows how Hefei Lifeon Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2025. As of June 2026, the ratio stands at 36.9%, reflecting working capital of CN¥730.06 Million against net assets of CN¥1.98 Billion CNY. See operational self-sufficiency of Hefei Lifeon Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
Hefei Lifeon Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2012–2025)
Hefei Lifeon Pharmaceutical Co Ltd working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Hefei Lifeon Pharmaceutical Co Ltd from 2012 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 003020 total asset value.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 33.6% | CN¥655.66 Million | CN¥1.95 Billion | CN¥1.18 Billion | CN¥520.58 Million | ▲ +2.0 pp |
| 2024 | 31.6% | CN¥603.54 Million | CN¥1.91 Billion | CN¥1.19 Billion | CN¥581.95 Million | ▼ -0.9 pp |
| 2023 | 32.5% | CN¥608.42 Million | CN¥1.87 Billion | CN¥1.15 Billion | CN¥542.73 Million | ▼ -23.6 pp |
| 2022 | 56.1% | CN¥829.92 Million | CN¥1.48 Billion | CN¥1.45 Billion | CN¥622.63 Million | ▼ -12.3 pp |
| 2021 | 68.4% | CN¥891.59 Million | CN¥1.30 Billion | CN¥1.22 Billion | CN¥328.05 Million | ▼ -12.5 pp |
| 2020 | 80.9% | CN¥949.61 Million | CN¥1.17 Billion | CN¥1.29 Billion | CN¥342.35 Million | ▲ +10.8 pp |
| 2019 | 70.1% | CN¥413.41 Million | CN¥590.00 Million | CN¥694.83 Million | CN¥281.42 Million | ▲ +0.1 pp |
| 2018 | 69.9% | CN¥353.73 Million | CN¥505.70 Million | CN¥605.54 Million | CN¥251.82 Million | ▲ +12.4 pp |
| 2017 | 57.6% | CN¥208.17 Million | CN¥361.71 Million | CN¥439.65 Million | CN¥231.47 Million | ▲ +11.1 pp |
| 2016 | 46.4% | CN¥138.36 Million | CN¥298.09 Million | CN¥375.00 Million | CN¥236.64 Million | ▲ +18.8 pp |
| 2014 | 27.6% | CN¥59.57 Million | CN¥215.53 Million | CN¥313.20 Million | CN¥253.63 Million | ▲ +4.8 pp |
| 2013 | 22.8% | CN¥40.39 Million | CN¥176.88 Million | CN¥307.27 Million | CN¥266.88 Million | ▼ -5.6 pp |
| 2012 | 28.4% | CN¥40.33 Million | CN¥141.96 Million | CN¥256.00 Million | CN¥215.67 Million | — |